Abstract:Background: The outbreaks of emerging infectious diseases caused by pathogens such as SARS coronavirus, H5N1, H1N1, and recently H7N9 influenza viruses, have been associated with significant mortality and morbidity in humans. Neutralizing antibodies from individuals who have recovered from an infection confer therapeutic protection to others infected with the same pathogen. However, survivors may not always be available for providing plasma or for the cloning of monoclonal antibodies (mAbs).Methodology/Principal Findings: The genome and the immunoglobulin genes in rhesus macaques and humans are highly homologous; therefore, we investigated whether neutralizing mAbs that are highly homologous to those of humans (human-like) could be generated. Using the H5N1 influenza virus as a model, we first immunized rhesus macaques with recombinant adenoviruses carrying a synthetic gene encoding hemagglutinin (HA). Following screening an antibody phage display library derived from the B cells of immunized monkeys, we cloned selected macaque immunoglobulin heavy chain and light chain variable regions into the human IgG constant region, which generated human-macaque chimeric mAbs exhibiting over 97% homology to human antibodies. Selected mAbs demonstrated potent neutralizing activities against three clades (0, 1, 2) of the H5N1 influenza viruses. The in vivo protection experiments demonstrated that the mAbs effectively protected the mice even when administered up to 3 days after infection with H5N1 influenza virus. In particular, mAb 4E6 demonstrated sub-picomolar binding affinity to HA and superior in vivo protection efficacy without the loss of body weight and obvious lung damage. The analysis of the 4E6 escape mutants demonstrated that the 4E6 antibody bound to a conserved epitope region containing two amino acids on the globular head of HA.Conclusions/Significance: Our study demonstrated the generation of neutralizing mAbs for potential application in humans in urgent preparedness against outbreaks of new influenza infections or other virulent infectious diseases.

Development of a Safe and Convenient Neutralization Assay for Rapid Screening of Influenza HA-specific Neutralizing Monoclonal Antibodies.

Generation of Neutralizing and Non-Neutralizing Monoclonal Antibodies Against H7N9 Influenza Virus.

Evaluation of Panel of Neutralising Murine Monoclonal Antibodies and a Humanised Bispecific Antibody Against Influenza A(H1N1)pdm09 Virus Infection in a Mouse Model.

Rapid Generation Of Human-Like Neutralizing Monoclonal Antibodies In Urgent Preparedness For Influenza Pandemics And Virulent Infectious Diseases

Safe Pseudovirus-Based Assay for Neutralization Antibodies Against Influenza A(H7N9) Virus.

Development of an Antigen-Capture Enzyme-Linked Immunosorbent Assay and Immunochromatographic Strip Based on Monoclonal Antibodies for Detection of H6 Avian Influenza Viruses

Antigen-capture ELISA and immunochromatographic test strip to detect the H9N2 subtype avian influenza virus rapidly based on monoclonal antibodies

Development of a monoclonal antibody-based antigen capture enzyme-linked immunosorbent assay for detection of H7N9 subtype avian influenza virus

Generation of Human Neutralizing Monoclonal Antibodies Against the 2009 Pandemic H1N1 Virus from Peripheral Blood Memory B Lymphocytes.

Generation and Characterization of Monoclonal Antibodies Against the Hemagglutinin of H3N2 Influenza A Viruses.

Preparation and characterization of mouse-derived monoclonal antibodies against the hemagglutinin of the H1N1 influenza virus

The generation of hemagglutinin monoclonal antibodies against H9N2 influenza virus

Characterization of Neutralizing Monoclonal Antibodies and Identification of a Novel Conserved C-Terminal Linear Epitope on the Hemagglutinin Protein of the H9N2 Avian Influenza Virus

Identification and Structural Characterization of a Broadly Neutralizing Antibody Targeting a Novel Conserved Epitope on the Influenza Virus H5N1 Hemagglutinin

Characterization of Monoclonal Antibodies Against Ha Protein of H1n1 Swine Influenza Virus and Protective Efficacy Against H1 Viruses in Mice

Feasibility and importance of developing broadly neutralizing antibodies for clinical use against influenza viruses

[Generation of Neutralizing Recombinant Human Antibodies for Targeting Highly Pathogenic Avian Influenza A (H5N1) Virus].

Characterization of a Broad-spectrum Neutralization Monoclonal Antibody Against Haemagglutinin of H5 Subtype Avian Influenza Virus

Generation, Characterization and Epitope Mapping of Two Neutralizing and Protective Human Recombinant Antibodies Against Influenza A H5N1 Viruses.

A rapid and flexible microneutralization assay for serological assessment of influenza viruses

Rapid Isolation of a Potent Human Antibody Against H7N9 Influenza Virus from an Infected Patient